Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Nabil Wasif

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7979-6766; OpenAlex author ID A5018631751. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 7 papers

Papers 11

  1. The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer. Co-author DOI 10.1002/jso.70361↗
  2. Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma With Persistent Lymphovascular Invasio… Co-author DOI 10.1002/jso.70414↗
  3. The Neoadjuvant Window: Serial Assessment of Sarcopenia During Treatment for Pancreatic Cancer. Co-author DOI 10.1177/00031348261495994↗
  4. Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Co-author DOI 10.1245/s10434-026-19739-2↗
  5. ASO Visual Abstract: Do Postoperative Complications Impact Adjuvant Chemotherapy for Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Co-author DOI 10.1245/s10434-026-19795-8↗
  6. Correction: Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Co-author DOI 10.1245/s10434-026-20347-3↗
  7. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter? Co-author DOI 10.6004/jnccn.2025.7097↗
  8. Pancreatic cancer mortality trends in the United States: how much have we moved the needle? Co-author DOI 10.21037/jgo-24-213↗
  9. Association of Textbook Outcome and Surgical Case Volume with Long-Term Survival in Patients Undergoing Surgical Resection for Pancreatic Cancer: In Reply to L… Co-author DOI 10.1097/xcs.0000000000000749↗
  10. Association of Textbook Outcome and Surgical Case Volume with Long-Term Survival in Patients Undergoing Surgical Resection for Pancreatic Cancer. Last author DOI 10.1097/xcs.0000000000000407↗
  11. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. Last author DOI 10.1007/s11605-014-2566-5↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chee‐Chee Stucky · 9 shared papers, 2022–2026 · strength 2.36
  2. Zhi Ven Fong · 8 shared papers, 2024–2026 · strength 2.16
  3. Richard J. Bold · 5 shared papers, 2026 · strength 1.33
  4. Yu-Hui H. Chang · 4 shared papers, 2022–2026 · strength 1.18
  5. Dillon C. Cheung · 4 shared papers, 2026 · strength 1.09
  6. Stephanie Yu · 3 shared papers, 2026 · strength 0.79
  7. Mitesh J. Borad · 1 shared paper, 2026 · strength 0.30
  8. Kumaresan Sandrasegaran · 1 shared paper, 2026 · strength 0.30
  9. Valerie L. Armstrong · 1 shared paper, 2026 · strength 0.30
  10. Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.30
  11. Rahul Pannala · 1 shared paper, 2026 · strength 0.29
  12. Patricia G Lu · 1 shared paper, 2026 · strength 0.29
  13. Cho‐Han Chiang · 1 shared paper, 2024 · strength 0.24
  14. Jia Yi Tan · 1 shared paper, 2024 · strength 0.24
  15. Po Hong Tan · 1 shared paper, 2026 · strength 0.24
  16. John Andrew Stauffer · 1 shared paper, 2026 · strength 0.24
  17. Susanne Gray Warner · 1 shared paper, 2026 · strength 0.24
  18. Michael L. Kendrick · 1 shared paper, 2026 · strength 0.24
  19. Cornelius A. Thiels · 1 shared paper, 2026 · strength 0.24
  20. Mark Joseph Truty · 1 shared paper, 2026 · strength 0.24
  21. Katherine E. Poruk · 1 shared paper, 2026 · strength 0.24
  22. Roshini Kalagara · 1 shared paper, 2022 · strength 0.20
  23. Awais Ashfaq · 1 shared paper, 2014 · strength 0.06
  24. Thorvardur Ragnar Halfdanarson · 1 shared paper, 2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.